Condition: Kaposi Sarcoma · Skin · Sponsor: AIDS Malignancy Consortium
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This description comes directly from the study's public registry record.
Erin Reid, MD · (858) 822-6100 · egreid@ucsd.edu
Always discuss trial participation with your own doctor first.
| UC San Diego | San Diego, California, United States | Recruiting |
| Zuckerberg San Francisco General Hospital | San Francisco, California, United States | Recruiting |
| University of Miami Miller School of Medicine | Miami, Florida, United States | Recruiting |
| University of Illinois Cancer Center | Chicago, Illinois, United States | Recruiting |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Mount Sinai Hospital | New York, New York, United States | Recruiting |
| Abramson Cancer Center at Pennsylvania Hospital | Philadelphia, Pennsylvania, United States | Recruiting |
| Thomas Street Clinic | Houston, Texas, United States | Recruiting |
| Thomas Street Clinic | Houston, Texas, United States | Recruiting |
| Virginia Mason Medical Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04305691